---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023470"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:15:20.377764+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Delcath Q1 revenue surges to $19.8M, posts net income of $1.1M vs loss a year ago

## Summary
- Total revenue $19.8M (vs $3.1M Q1 2024); HEPZATO KIT sales $18.0M, CHEMOSAT $1.8M.
- Net income $1.1M vs net loss of $11.1M in prior-year quarter; gross margin 86%.
- Non-GAAP adjusted EBITDA $7.6M vs loss of $7.3M in Q1 2024.
- Cash and investments $58.9M, no debt; exercise of Series F warrants added $16.2M.
- 19 active U.S. centers; FDA cleared IND for phase 2 HEPZATO in metastatic breast cancer.

## SEC filing metadata
- accession: 0001628280-25-023470
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828025023470/0001628280-25-023470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828025023470/dcth-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023470
- JSON: https://secwatch.observer/filing/0001628280-25-023470.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.